Myeloid cell leukemia sequence 1 (MCL1), an anti-apoptotic BCL2 family protein, is a key regulator of intrinsic apoptosis. Normal cells require strict control over MCL1 expression with aberrant MCL1 expression linked to the emergence of various diseases and chemoresistance. Previous studies have detailed how MCL1 expression is regulated by multiple mechanisms both transcriptionally and translationally. However, characterization of the post-transcriptional regulators of MCL1 mRNA is limited. Polypyrimidine tract binding protein 1 (PTBP1) is a known regulator of post-transcriptional gene expression that can control mRNA splicing, translation, stability and localization. Here we demonstrate that PTBP1 binds to MCL1 mRNA and that knockdown of PTBP1 upregulates MCL1 expression in cancer cells by stabilizing MCL1 mRNA and increasing MCL1 mRNA accumulation in cytoplasm. Further, we show that depletion of PTBP1 protects cancer cells from antitubulin agent-induced apoptosis in a MCL1-dependent manner. Taken together, our findings suggest that PTBP1 is a novel regulator of MCL1 mRNA by which it controls apoptotic response to antitubulin chemotherapeutics. Apoptosis, a highly regulated process of programmed cell death, is essential for maintaining tissue homeostasis and development. Dysregulation of apoptosis leads to a number of pathophysiologies including neurodegenerative diseases, inflammatory disorders, oncogenesis, and chemoresistance of certain malignancies.
Apoptosis, a highly regulated process of programmed cell death, is essential for maintaining tissue homeostasis and development. Dysregulation of apoptosis leads to a number of pathophysiologies including neurodegenerative diseases, inflammatory disorders, oncogenesis, and chemoresistance of certain malignancies. 1 The B-cell lymphoma 2 BCL2 family of both pro-and anti-apoptotic proteins are regulators of intrinsic apoptosis which is responsible for cellular response to DNA damage, mitotic failure and homeostatic stress. 2 The importance of the BCL2 family was recognized soon after the initial identification of the BCL2 gene wherein an aberrant chromosomal translocation leads to its upregulation in human follicular lymphoma. 3, 4 More than 30 proteins sharing common sequence motifs with BCL2, most importantly a BH3 (BCL2 homology 3) helix, have subsequently been identified and are grouped together as the BCL2 family. 5 The family is divided into three sub-families: anti-apoptotic, pro-apoptotic and pro-apoptotic BH3-only. BCL2 family regulation centers on the ability of the six anti-apoptotic BCL2 family members (BCL2, BCLXL, BCLW, MCL1 BCLB, and BFL1/A1) to bind the BH3 helices of the pro-apoptotic BCL2 proteins, BAX and BAK (BCL2 homologous antagonist/killer), thereby sequestering them in an inactive state. Multiple cellular stress pathways induce expression of one or a set of the pro-apoptotic BH3-only family members. These BH3-only proteins negatively regulate the anti-apoptotic BCL2 family members by competitively binding their BH3 binding pockets. A subset of BH3-only proteins has also been shown to directly activate BAX or BAK oligomerization. 2, 5 Upregulation of the anti-apoptotic BCL2 family members has been observed across the cancer landscape 6, 7 and is a recognized method for tumors to evade chemotherapeutic induced intrinsic apoptotic signaling. 8, 9 MCL1, one of the anti-apoptotic BCL2 proteins and a homolog of BCL2, was first identified as a gene upregulated during differentiation of a myeloid leukemia cell line. 10 It is unique among the BCL2 family due to its short half-life at both the mRNA and protein levels. 1, 11 MCL1 is essential for normal homeostasis, as its knockdown in mice has been shown to impair neuronal differentiation 12 and blood cell maturation. 13 Further, MCL1 exhibits high expression in solid tumors 6 and its overexpression has been shown to suppress cell death during extended mitotic arrest induced by microtubuletargeting agents such as taxanes and Vinca alkaloids. 8, 9 MCL1 is strictly regulated by multiple mechanisms. Recent studies of the transcriptional control of MCL1 have tied its expression to multiple transcription factors (e.g., STAT3, STAT5, PU.1, HIF1 and E2F1). [14] [15] [16] [17] [18] Other studies have identified multiple proteins that regulate the translation of MCL1 (CUGBP2, eIF2α and mTORC1). [19] [20] [21] Further research has shown that MCL1 protein stability is regulated through binding by the BH3-only protein NOXA 8, 22 and ubiquitinmediated degradation through the E3-ligase Mule. 23, 24 Together, this body of research has provided key insight into the importance of MCL1 regulation in normal and cancer biology. Yet, while these studies have established the importance of identifying regulators of MCL1 expression, few details regarding the protein regulators of MCL1 on posttranscriptional levels such as mRNA stability and subcellular distribution have been described.
The MCL1 mRNA contains a long 3′-untranslated region (3′UTR) of~2800 bases. 3′UTRs often contain regulatory regions that mediate protein-mRNA interactions that affect mRNA stability, translation, and localization. A number of micro-RNAs (miRNAs) have been proven to target the MCL1 3′UTR for degradation. [25] [26] [27] Although identification of proteins that modulate MCL1 mRNA stability and localization has been limited. One key regulator of mRNA is polypyrimidine tract binding protein 1 (PTBP1; also known as PTB or HNRNPI). PTBP1 is a RNA binding protein that regulates RNA splicing, IRES (internal ribosome entry segment)-mediated translation initiation, 3′-end processing, mRNA turnover, localization, and transportation.
28 PTBP1 has been shown to be involved in distinct cellular processes including T-cell activation, 29 HCV replication and infection, 30 insulin secretion, 31 and apoptosis [32] [33] [34] through its post-transcriptional control of RNA. Recent studies have highlighted that PTBP1 expression is often dysregulated in human cancer, though its effect on malignancy appears to be cell-type dependent. [35] [36] [37] In addition, it has been shown that PTBP1 knockdown can protect cancer cells from TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis. 32, 33 Our initial analysis of available cross-linking immunoprecipitation sequencing (CLIP-SEQ) data (GSM1048186 38 ) identified a strong association between PTBP1 and MCL1 mRNA with extensive interactions at the MCL1 3′UTR (Figure 1a) . Therefore, the objective of the current study was to determine the effect that PTBP1 binding has on MCL1 mRNA and how this effect may influence cancer cell response to chemotherapeutics.
Results
PTBP1 binds to MCL1 mRNA. To investigate the possible interaction between PTBP1 and MCL1 mRNA, we analyzed publicly available CLIP-SEQ data 38 on genome-wide PTBP1-RNA interactions in HeLa cells. This analysis identified multiple sites of association between PTBP1 and MCL1 mRNA especially in its 3′UTR (Figure 1a) . The interaction between PTBP1 and MCL1 mRNA was subsequently confirmed in the PC3 cell line (Figure 1b ) using RNA immunoprecipitation (RIP).
Knockdown of PTBP1 upregulates MCL1 expression. As a first step to understanding the effect that PTBP1 has on MCL1 mRNA, we assessed how changes in PTBP1 expression regulate MCL1 expression. For these studies we chose five human cancer cell lines from different tissue types-PC3 (prostate), H1299 (lung), A549 (lung), LN229 (CNS) and MCF7 (breast). We transfected each cell line with either negative control siRNA (siControl); one of two individual PTBP1-specific siRNA (siPTBP1#1 or siPTBP1#2); or a mixture of the two siPTBP1 and analyzed MCL1 protein levels by western blotting (Figure 2a ) and MCL1 mRNA levels by real-time quantitative PCR (RT-qPCR; Figure 2b ) 48 h after introduction of the siRNA. The mixture of siPTBP1#1 and siPTBP1#2 was used for all subsequent PTBP1 knockdowns and that mixture is hereafter referred to as siPTBP1. Knockdown of PTBP1 induced a significant upregulation of both MCL1 protein and mRNA in each of these cell lines. Overexpression of a Flag-PTBP1 construct in either PC3 cells or H1299 cells did not induce a significant change in MCL1 expression (Supplementary Figure S1) .
To demonstrate that the increase in MCL1 expression was due to PTBP1 knockdown and not an off-target effect of the siRNAs, we performed a rescue experiment using the siPTBP1#1, which targets the 3′UTR of PTBP1, in H1299 cells. For this experiment we first transfected H1299 cells with Flag-PTBP1 or Flag control. After 24 h we then treated the cells with siPTBP1#1 and measured both PTBP1 and MCL1 levels an additional 24 h later (Figure 2c ). This alternate siPTBP1#1 treatment resulted in a less complete knockdown of PTBP1, but still resulted in increased expression of MCL1. Further, we observed that overexpression of Flag-PTBP1, lacking the PTBP1 3′UTR, in H1299 cells returned MCL1 expression to normal levels following siPTBP1#1 treatment (Figure 2c ).
MCL1 mRNA can be alternatively spliced to produce a shortened form of MCL1, MCL1S. Unlike MCL1, MCL1S is pro-apoptotic. 39 As PTBP1 is a well-known splicing regulator, we designed MCL1S specific primers to determine if knockdown of PTBP1 could also regulate MCL1S expression. However, in all five human cancer cell lines, we observed no evidence of MCL1S protein by western blotting nor mRNA by RT-qPCR in either siControl or siPTBP1-treated cells.
Knockdown of PTBP1 increases MCL1 mRNA stability. PTBP1 binding to mRNA has been reported in many cases to regulate mRNA turnover. 26, 38 On the basis of the observed PTBP1 binding to MCL1 mRNA (Figure 1 ) and increase in MCL1 mRNA levels following PTBP1 knockdown (Figure 2b ), we hypothesized that knockdown of PTBP1 stabilized MCL1 mRNA. To test this, siControl and siPTBP1 cells were treated with actinomycin D (Act. D) to block transcription and incremental RNA samples were harvested to assess MCL1 mRNA half-life. Prior studies have observed 40 and our data confirm that GAPDH mRNA levels remain constant over the 8 h observation window in both PC3 and H1299 cells. MCL1 mRNA levels were therefore normalized to GAPDH levels in RT-qPCR and the relative MCL1 mRNA levels at 0 h were defined to be 100%. Linear regression decay curves of MCL1 mRNA ( Figure 3 ) demonstrated a 1.6-and 1.8-fold increase in half-life for siPTBP1 treated PC3 and H1299 cells, respectively.
PTBP1 knockdown does not affect MCL1 protein stability. In addition to increasing MCL1 mRNA, knockdown of PTBP1 also increased MCL1 protein levels (Figure 2a) .
Although prior studies have not identified PTBP1 regulation of protein stability directly, we next sought to determine if PTBP1 regulation of proteins known to affect MCL1 protein stability affected MCL1 expression. We used cycloheximide (CHX) to block protein synthesis and determined the MCL1 protein decay curve by collecting and analyzing protein lysates at different time points after CHX treatment by western blotting. In each cell line, siControl or siPTBP1 treated, MCL1 half-life was unchanged at 30 and 45 min for PC3 and H1299 cells, respectively ( Figure 4 ). These data show that PTBP1 knockdown does not affect MCL1 protein half-life in either PC3 or H1299 cells. This suggests that PTBP1 regulation of MCL1 expression occurs at the mRNA level and does not function through upstream regulation of proteins involved in MCL1 protein turnover. The statistical significance was determined by unpaired student t-test where *Po0.05; **Po0.01; ***Po0.001
PTBP1 depletion increases MCL1 mRNA accumulation in cytoplasm. In addition to its role in regulating mRNA stability, PTBP1 is also known to regulate mRNA localization in cells. For instance, PTBP1 is required for correct Vg1 RNA localization in Xenopus oocytes during cytoplasmic RNA transport. 41 Similar studies have demonstrated PTBP1's ability to regulate subcellular distribution of STX1B, VAMP2, SV2A, KIF5 and CD40L mRNA. 29, 42 To determine whether PTBP1 influenced MCL1 mRNA cellular distribution, we performed nucleo-cytoplasmic fractionation of both protein and RNA in siControl and siPTBP1 cells. Both protein lysates and RNA extracts from whole-cell, cytoplasmic and nuclear fractions were collected. To confirm PTBP1 depletion efficiency and fractionation quality, equal volumes of the protein lysates were then separated on SDS-PAGE and immunoblotted for PTBP1, MCL1, Lamin A/C (nuclear control), and GAPDH (cytoplasmic control). Knockdown of PTBP1 did not influence MCL1 protein subcellular localization (Figure 5a) . To assess the impact on MCL1 mRNA, we analyzed equal amounts of cytoplasmic or nuclear RNA extracts by RT-qPCR using GAPDH as an internal control. In each cell line, cytoplasmic total RNA was approximately four times that of nuclear RNA following subcellular fractionation. To assess fold change of MCL1 mRNA levels in both cytoplasmic and nuclear fractions following siPTBP1 treatment, both relative cytoplasmic and nuclear MCL1 mRNA levels in siControl cells were set as one. Knockdown of PTBP1 significantly increased MCL1 mRNA levels in the cytoplasm of both PC3 and H1299 cell lines (Figure 5b) . In PC3 cells, MCL1 mRNA levels in cytoplasm increased markedly but the nuclear levels did not change (Figure 5b , left). In H1299 cells, although both the cytoplasmic and nuclear MCL1 mRNA levels increased, the increase in cytoplasm was significantly higher than that in nucleus (Figure 5b, right) . These data suggest that in addition to increasing MCL1 mRNA levels, knockdown of PTBP1 also affects cellular localization of MCL1 mRNA.
PTBP1 downregulation protects cancer cells from antitubulin agents in a MCL1-dependent manner. Prior studies have demonstrated that PTBP1 knockdown suppresses TRAIL-induced apoptosis in human cancer cells. 32, 33 TRAIL has previously been identified as an extrinsic apoptotic activator. 43 Further, PTBP1 has been reported to be involved in intrinsic apoptosis. 34, 44 On the basis of our data demonstrating that PTBP1 knockdown increases MCL1 expression we firstly sought to determine if PTBP1 knockdown is pro-survival due to its upregulation of MCL1. For these studies we used antitubulin agents, docetaxel and The MCL1 protein decay curves were generated using one-phase exponential decay in Graphpad Prism. Each point was presented as mean ± S.E.M., n = 3 vincristine, as apoptotic inducers. Antitubulin chemotherapeutics are widely used for many solid tumor types including breast cancer, prostate cancer and non-small cell lung cancer. 45 The established antitubulin agents are mostly from two mechanistically different classes, taxanes (e.g., docetaxel) and Vinca alkaloids (e.g., vincristine). They cause mitotic arrest by stabilizing microtubules, which induces a cell cycle block and apoptosis. 46 After treating siControl and siPTBP1 PC3 cells with 1000 nM docetaxel or 1000 nM vincristine for 48 h, siControl cells rounded up and underwent cell death while roughly half of PTBP1-depleted cells maintained a normal morphology (Figure 6a-c) . To quantify this effect, we measured the viability of PC3 cells using the CellTiter 96 AQueous One Solution Cell Proliferation (MTS) Assay (Promega, Madison, WI, USA) following siControl or siPTBP1 treatment. We found that PTBP1-depleted cells were less sensitive to both docetaxel and vincristine treatment exhibiting increased cell viability (Figure 6d) .
To test our hypothesis that this protective effect of PTBP1 knockdown is MCL1 dependent, we then knocked down both MCL1 and PTBP1 using siRNA and observed that siMCL1 (a mixture of two MCL1 targeted siRNAs) in PTBP1-depleted cells restored their sensitivity to both docetaxel and vincristine (Figure 6d ). In addition to silencing MCL1 expression by siRNAs, we selectively blocked the anti-apoptotic BCL2 family proteins using the BH3 mimetics ABT737 47 or Sabutoclax.
48
ABT737 displays high binding affinity to BCL2, BCLW, and BCLXL but not to MCL1. 47 Thus its efficacy is restricted to tumors with low levels of MCL1 and neutralization of MCL1 can re-sensitize resistant cancer cells to ABT737. 49 Due to this limitation in ABT737, Sabutoclax (BI-97C1) was recently identified with pan-BCL2 family inhibitory potency. 48 We firstly identified that 1000 nM ABT737 or 100 nM Sabutoclax could induce a small decrease in cell viability (shown as Abs 490 nm by MTS assay) which is not significantly different between cells treated with siControl and siPTBP1 (Figure 6e ). We then treated siControl or siPTBP1 PC3 cells with 1000 nM ABT737 or 100 nM Sabutoclax and measured dose-dependent cell viability under docetaxel-induced mitotic stress. Following BCL2, BCLXL, and BCLW inhibition by ABT737, knockdown of PTBP1 retained its protective role on cell death (Figure 6f,  left) . However, when all the anti-apoptotic BCL2 family members including MCL1 were inhibited using Satutoclax, the pro-survival effect of siPTBP1 was negated (Figure 6f , right). These data support that the pro-survival effect of PTBP1 knockdown to antitubulin agents is MCL1 dependent.
In order to determine if the protective mechanism of PTBP1 knockdown can be more broadly applied to other classes of apoptotic inducers, we also assessed the viabilities of siControl or siPTBP1 treated PC3 cells with increasing doses of the DNA damage inducer cisplatin by MTS assay. In this case we did not observe a siPTBP1 induced pro-survival effect (Supplementary Figure S2) .
Knockdown of PTBP1 decreases apoptosis by antitubulin agents in a MCL1-dependent manner. To confirm that the PTBP1 knockdown induced pro-survival effect was due to changes in the population of apoptotic cells, PC3 cells were treated with 10 nM docetaxel or 100 nM vincristine for 48 h, harvested and analyzed by Annexin V/PI (propidium iodide) staining followed by flow cytometry to measure the degree of apoptosis. Annexin V − /PI − cells (lower left quadrant) are considered viable while Annexin V+/PI − cells (lower right quadrant) are considered apoptotic (Figure 7a) . 50 We observed that the viability data from the Annexin V/PI staining was in agreement with the MTS data in that depletion of PTBP1 increased cell viability and depletion of PTBP1 and MCL1 together reversed siPTBP1's effects (Figures 6d  and 7a) . Further, siPTBP1 caused a 50% decrease in both docetaxel and vincristine induced apoptosis compared with siControl. This reduction in the apoptotic population following siPTBP1 treatment of cells effectively returned the percent apoptosis to basal levels (DMSO treatment) suggesting siPTBP1 treatment almost completely blocked the apoptotic effects of antitubulin chemotherapeutics (Figure 7a and b) . Although siMCL1+siPTBP1 together restored the apoptotic population (Figure 7a and b) . The knockdown efficiency of each siRNA in both the viability and apoptosis assays was confirmed by western blotting (Figure 7c ). The western blots revealed that siMCL1 in combination with siPTBP1 did not fully deplete MCL1 from the cell, as is seen during treatment with siMCL1 alone, but rather returned MCL1 levels to a basal (siControl) expression level in PC3 cells (Figure 7c ). We observed similar results in H1299 cells that knockdown of PTBP1 decreased apoptosis compared with siControl ( Supplementary Figure S3a and b) . In H1299 cells where siMCL1+siPTBP1 treatment reduced MCL1 Figure 5 Downregulation of PTBP1 increases the cytoplasmic MCL1 mRNA levels more significantly. Cytoplasmic (C) and nuclear (N) fractions were prepared from PC3 and H1299 cells transfected with either siControl or a mixture of two siPTBP1 for 48 h. Whole-cell protein and RNA extracts (W) were also collected. (a) Protein fractions were analyzed by western blotting to show both the subcellular fractionation quality and that PTBP1 knockdown had no effect on MCL1 protein distribution in cells. GAPDH and Lamin A/C were used as the cytoplasmic and nuclear markers, respectively. (b) RNA fractions were quantified by RT-qPCR using GAPDH as the normalization control. Both relative cytoplasmic and nuclear MCL1 mRNA levels in siControl cells were set as one. Data are shown as mean ± S.E.M., n = 4. The statistical significance was determined by unpaired student t-test where *Po0.05; **Po0.01; ***Po0.001 expression to levels comparable to siMCL1 treatment alone (Supplementary Figure S3c) , there is no significant difference in apoptotic rates between siMCL1/siPTBP1 and siMCL1 alone. All data indicate that the anti-apoptotic effect of PTBP1 knockdown to antitubulin chemotherapeutics depends largely on its upregulation of MCL1.
Discussion
The influence of PTBP1 on apoptosis continues to emerge. Thus far, PTBP1 has been demonstrated to influence TRAIL-induced extrinsic apoptosis in cancer cells 32, 33 and caspase-dependent apoptosis during ischemia in cardiomyocytes. 44 Studies focused on the impact of PTBP1 on apoptotic regulatory genes have shown that changes in PTBP1 expression modulate: the expression of CASPASE-3, CASPASE-9, APAF1, BAX, and BID; 44 alternative splicing of BCLX into its pro-apoptotic (BCLXL) and anti-apoptotic (BCLXS) isoforms; 34 and activation of IRES-mediated translation during apoptosis. 32, 33 Our studies support the positioning of PTBP1 as a major regulator of apoptosis. We provide the first example that PTBP1 downregulation protects cancer cells were treated with 1000 nM ABT737 or 100 nM Sabutoclax combined with various doses of docetaxel for 48 h and cell viability was assessed by MTS assay. The viability of cells with 1000 nM ABT737 or 100 nM Sabutoclax alone was set as 100%. All data are presented as mean ± S.E.M., n = 3. The statistical significance was determined by unpaired student t-test where *Po0.05; **Po0.01; ***Po0.001 from apoptosis induced by mitotic stress (docetaxel and vincrinstine) and further that PTBP1 is not a general apoptosis suppressor as there is no similar effect following cisplatininduced DNA damage.
In regard to MCL1 mRNA regulation, these studies provide the first example of a protein that binds to MCL1 mRNA and regulates its mRNA stability. In addition, our findings show that PTBP1 downregulation changes the subcellular distribution of MCL1 mRNA. We observed both an increase in cytoplasmic MCL1 mRNAs and an increase in the cytoplasmic: nuclear ratio of MCL1 mRNA in PTBP1-depleted cells. The transcriptional and translational regulation of MCL1 has been extensively studied. Yet, thus far on the post-transcriptional level only miRNAs have been identified to regulate the half-life of MCL1 mRNA. [25] [26] [27] Further, the identification of protein regulators of MCL1 mRNA localization has been largely ignored. PTBP1 has previously been shown to influence miRNA association with mRNAs. 38 Further, a number of the regions identified in the published CLIP-SEQ study of PTBP1 in HeLa cells overlap with or neighbor known and putative miRNA sites in MCL1. Based on these studies and our results, detailed analysis of how different miRNAs that target MCL1 are influenced by PTBP1 and how overexpression or loss of one or a set of these may impact PTBP1 regulation of MCL1 mRNA could provide significant insight into the intricate control over MCL1 expression in normal homeostasis and cancer biology. Yet, the present study establishes that the regulation of MCL1 mRNA by proteins has significant impact on chemotherapeutic response and merits further study.
Recent studies have highlighted the critical positioning of MCL1 as a mitotic clock to balance cell death and survival during extended mitosis. 8, 9 Thus, in periods of prolonged mitosis induced by microtubule stabilizing compounds, increased MCL1 expression enables the cells to survive. Conversely, inhibition or depletion of MCL1 during a prolonged mitotic period has been shown to induce apoptosis and to synergistically combine with compounds that induce prolonged mitosis. 51 Our studies agree with these findings as we observed that PTBP1 depletion increased MCL1 expression, which protected cancer cells from apoptosis induced by antitubulin agents. Our analysis of both the prostate derived and lung derived cancer cell lines, PC3 and H1299, respectively shows that knockdown of MCL1 in PTBP1-depleted cells re-sensitizes the cells to docetaxel or vincristine. In addition, we show that when MCL1 is blocked by the pan-BCL2 family inhibitor Sabutoclax, the pro-survival effect of PTBP1 depletion is impaired completely. However, the BH3 mimetic inhibitor ABT737 which targets BCL2, BCLW, and BCLXL has no influence on the pro-survival role of PTBP1 knockdown to antitubulin chemotherapeutics. This effect may have significant implications in understanding PTBP1's roles during cancer progression and chemoresistance. In addition to its role in apoptosis regulation, MCL1 is also a key regulator of mitochondrial dynamics and metabolism. [52] [53] [54] [55] Our report that PTBP1 modulates MCL1 expression thus implicates a possible involvement of PTBP1 in regulating mitochondrial dynamics. Further examination of such an effect may prove to be of interest to the field. Finally, as decreased PTBP1 has been observed as a key event during neuron, 38 muscle 56 and cardiomyocyte 44 differentiation, its impact on MCL1 expression may serve as an important event during normal cellular development.
In summary, we have identified that downregulation of PTBP1 upregulates MCL1 expression both by increasing the half-life and cytoplasmic localization of MCL1 mRNA. Our data demonstrate that the chemo-protective effect of PTBP1 knockdown to antitubulin chemotherapeutics is due largely to this upregulation of MCL1.
Materials and Methods
Cell culture, siRNA and plasmid transfection. PC3, H1299, A549, LN229, and MCF7 cells were maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum, 2.05 mM L-glutamine, 100 units per ml each of penicillin and streptomycin, and 0.25 μg/ml of Fungizone antimycotic (Life Technologies, Carlsbad, CA, USA) in a humidified atmosphere with 5% CO 2 .
Silencer Select validated siRNAs and negative control siRNAs were purchased from Ambion (Carlsbad, CA, USA). The siRNA sequences are: siPTBP1#1 (s11435) CAGUUUACCUGUUUUUAAAtt, siPTBP1#2 (s11436) GCAUCACGCUCUCGAA GCAtt, siMCL1#1 (s8583) CCAGUAUACUUCUUAGAAAtt, and siMCL1#2 (s8585) GTAATTAGGAACCTGTTTCtt. As a negative control, Silencer Select Negative Control #1 siRNA was used with no significant sequence similarity to human gene sequences. cDNA for PTBP1 (clone ID: 3863892) was obtained from Life Technologies and the coding sequence was cloned into the pcDNA3.1 plasmid with a Flag tag at the N terminus using a pcDNA 3.1 TOPO TA Expression Kit (Invitrogen, Carlsbad, CA, USA) for exogenous expression. siRNA and plasmid transfections were carried out using Lipofectamine RNA iMAX reagents and Lipofectamine 3000 reagents (Life Technolgies), respectively. Cells were harvested for analysis after 48 or 72 h transfection as designated in text.
Chemicals. Docetaxel, Vincrisitine, Cisplatin, ABT737, and Sabutoclax were purchased from Selleck Chemicals (Houston, TX, USA).
RT-qPCR. Total RNA was isolated from cells by Trizol reagent (Life Technologies) and purified by PureLink RNA Mini Kit (Ambion). Genomic DNA was removed using RNAse-free DNAse treatment. Final RNA concentrations were measured by absorbance at 260 nm and quality was confirmed using a A260/280 ratio of~2.0. cDNA was prepared using 1 μg of total RNA in 20 μl reverse transcription reaction with qScript cDNA SuperMix (Quanta Biosciences, Gaithersburg, MD, USA) according to manufacturer's protocol.
RT-qPCR reactions were performed in a 10 μl reaction containing 4 μl of the diluted cDNA, 5 μl PerfeCta SYBR green FastMix, Low ROX (Quanta Biosciences), and 0.5 μl each of forward and reverse primers at final concentrations of 250 nM. All qPCR reactions were run in quadruplicate on MicroAmp Optical 384-well plates on a ViiA7 instrument (Applied Biosystems, Carlsbad, CA, USA). Amplification conditions consisted of the initial denaturation step at 95°C for 3 min, followed by 40 cycles of 10 s at 95°C and 30 s at 60°C. Afterwards, melting curves were generated to confirm presence of a single uniform peak. Results were analyzed in ViiA 7 software by comparative CT (ΔΔCT) method using GAPDH as a normalization control and exported for analysis and presentation in GraphPad Prism (GraphPad Software, La Jolla, CA, USA).
The following primers (5′-3′) were used: MCL1: (F) GGACATCAAAAACGAAGACG and (R) GCAGCTTTCTTGGTTTATGG; PTBP1: (F) ATTGTCCCAGATATAGCCGTTG and (R) GCTGTCATTTCCGTTTGCTG; GAPDH: (F) CCACATCGCTCAGACACCAT and (R) CCAGGCGCCCAATACG; MCL1S: (F) GCCTTCCAAGGATGGGTTTGTG and (R) CAAACCAGCTCCTACTCC AGCA.
Protein extraction and western blot. Whole-cell lysates were prepared by lysating cells on ice with lysis buffer (Pierce, Rockford, IL, USA): 25 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP40, and 5% glycerol supplemented with protease inhibitors (1 mM AEBSF, 0.8 μM aprotinin, 0.05 mM bestatin, 0.015 mM E-64, 0.02 mM leupeptin, 0.01 mM pepstatin A).
Protein lysates were resolved by SDS-PAGE and transferred to PVDF membrane in a wet transfer system for 1 h at 100 V. Membranes were incubated with anti-MCL1 Abs (D35A5, Cell Signaling, Danvers, MA, USA), anti-PTBP1 Abs (RN011P, MBL International, Woburn, MA, USA), anti-β-actin Abs (PA1-21167, Pierce, Rockford, IL, USA), and anti-Lamin A/C Abs (H-110, Santa Cruz, Santa Cruz, CA, USA) at a dilution of 1 : 1000, and anti-GAPDH Abs (MAB373, Millipore, Billerica, MA, USA) at a dilution of 1 : 10 000 at 4°C overnight. HPR-conjugated secondary Abs were used for detection using ECL2 reagent (Pierce). Immunoblots were visualized on Bio-Rad ChemiDoc MP imaging system. Band intensities were quantified using Bio-Rad Image Lab software. Subcellular fractionation. Subcellular fractionation was performed by firstly suspending cells in hypotonic buffer A (10 mM Hepes pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 0.15% Triton X-100, protease inhibitor) and swollen on ice for 8 min. After spinning down for 30 s at 12 000 × g, supernatant was saved as the cytoplasmic fraction. Cytoplasmic RNA was isolated by Trizol and cytoplasmic protein lysates can be used immediately. The nuclear pellet was rinsed with cold PBS once. For the nuclear protein extraction, pellets were lysed with equal volume of buffer B (20 mM Hepes pH 7.9, 400 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 0.5% Triton X-100, protease inhibitor) on ice for 15 min. For nuclear RNA extraction, pellets were directly lysed by Trizol. Equal volumes of cytoplasmic and nuclear protein fractions were analyzed by western blot. Cytoplasmic and nuclear RNA fractions were analyzed by RT-qPCR using GAPDH as the normalization control.
RNA immunoprecipitation. RNA IP was done in PC3 cells using the RiboCluster Profiler RIP-Assay Kit (MBL International). In brief, cell extracts were incubated with anti-PTBP1-Abs (RN011P, MBL International) immobilized with protein A magnetic beads (Dynabeads, Thermo Fisher, Waltham, MA, USA), and the RNA-protein complex was then eluted. RNA was isolated and target RNA was analyzed by RT-PCR as outlined above.
mRNA and protein decay analysis. RNA stability was measured by incubating cells with 10 μg/ml Act. D and extracting total RNA at different time point. RT-qPCR was carried out to get relative RNA levels remaining (%) after Act.D treatment using GAPDH as the internal control. mRNA half-life was calculated by transforming the percentage of RNA levels remaining to log scale and linear regression of the mRNA decay in Graphpad Prism.
Protein stability was measured by treating cells with 5 μg/ml of cycloheximide and extracting total protein lysates at different time point. Total cell lysates (20 μg) were analyzed by western blotting and MCL1 and β-actin band intensities were quantified by Bio-Rad Image Lab. Percent MCL1 protein level remaining was calculated by setting the band intensity at 0 h as one and using β-actin band intensity as the internal control.
MTS assay. CellTiter 96 AQueous One Solution Cell Proliferation (MTS) Assay (Promega) was performed according to manufacturer's protocol. Viability (%) was calculated from the absorbance (490 nm) at different docetaxel/vincristine doses. Medium control absorbance (490 nm) was subtracted as the background read.
Flow cytometry. PC3 cells (2 × 10 5 ) were transfected with control siRNA or siPTBP1 alone or siMCL1 alone or siPTBP1 plus siMCL1. After 24 h, cells were treated with 0.1% DMSO as control or 10 nM docetaxel/100 nM vincristine in 0.1% DMSO for 48 h. Cells were trypsinized and 1 × 10 5 cells were stained with Annexin V-FITC and PI (BD Biosciences, San Jose, CA, USA) at room temperature for 15 min. Then cells were subjected to flow cytometry on BD LSRFortessa FACS, 50 000 events were collected for each sample and data was analyzed by FlowJo V10.
Statistical analysis. Statistical analysis was performed in Prism, Graphpad or Microsoft Excel. Unpaired Student t-test was used for all the statistical analysis. *Po0.05, **Po0.01, ***Po0.001.
